Work

Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.7050

Authors: Joseph G. Jurcic, Farhad Ravandi, John M. Pagel, Jae Hong Park, B. Douglas Smith, Dan Douer, Moshe Yair Levy, Elihu Estey, Hagop M. Kantarjian, Dennis Earle, Dragan Cicic, David A. Scheinberg

Institutions: Columbia University Irving Medical Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Washington, Actinium Pharmaceuticals (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2514789970

Cites:

Cited by: 27

Related to: 10